ZIB

Hits per page

hits 1 - 2 | 2 hits

Sorting

Electronic Resource

Programs for phasing by entropy maximization as implemented in Xtal3.2: a crystallographic software system (1993)

Stewart, J. M. ; Collins, D. M. ; Watenpaugh, K. D. ; [et al.]

Copenhagen : International Union of Crystallography (IUCr)

Acta crystallographica 49 (1993), S. 100-106

add to mindlist on the mindlist

Details

ISSN: 1399-0047

Source: Crystallography Journals Online : IUCR Backfile Archive 1948-2001

Topics: Chemistry and Pharmacology , Geosciences , Physics

Notes: Xtal3.2, a crystallographic software package, is an international development project involving about 40 researchers over a full spectrum of crystallographic interests. This development has been supported by many national and international agencies and commercial institutions since the first version in 1983. The 1992 release, Xtal3.2, contains software for 95 different calculations. These range from the processing of raw diffraction data to interactive molecular graphics, atomic charge estimation, electronic publication preparation, and the structure solution and refinement of small and large molecules. Tests of the Xtal programs for phase determination and phase refinement by the application of `maximum entropy' are presented.

Type of Medium: Electronic Resource

URL: http://dx.doi.org/10.1107/S0907444992008898

Permalink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

Electronic Resource

Evaluation of cutaneous algogenic responses to bradykinin and inhibition by bradykinin analogs (1992)

Schneider, B. K. ; Morelli, J. G. ; Vavrek, R. J. ; [et al.]

Springer

Archives of dermatological research 284 (1992), S. 1-4

add to mindlist on the mindlist

Details

ISSN: 1432-069X

Keywords: Algogenic ; Bradykinin ; Bradykinin analogs

Source: Springer Online Journal Archives 1860-2000

Topics: Medicine

Notes: Summary Bradykinin has long been postulated to have a major role in physiologic human pain production. We have developed a method to systematically quantify the algogenic response to bradykinin in human skin by the direct application of bradykinin to suction blister bases. After determination of the pain threshold to bradykinin, we examined the ability of synthetic peptide analogs of bradykinin to block bradykinin-induced pain. One of the six analogs (B4642) inhibited bradykinin-induced pain with at least one concentration in all subjects tested. This result could not be predicted on the basis of inhibition of bradykinin binding to its guinea-pig ileum receptor or to previous studies of bradykinin-induced pain production in animal models. This peptide may have an eventual role as a physiologic pain inhibitor.